Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative determination Soluble Mesothelin Related Peptides (SMRP) in human serum or plasma.
The assay utilizes proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Lumipulse® G Mesothelin Immunoreaction Cartridges
Product number 294192 3 x 14 Tests
Lumipulse® G Mesothelin Calibrators
Product number 233436 1 x 3 Concentrations
Lumipulse® G Specimen diluent 1
Product number 231203 4 x 300 mL
Excellent sensitivity: ≤ 0.1 nmol/L.
Excellent precision: Typical total CV's: < 6.0%
Wide dynamic range: 0.1 - 100 nmol/L
30-day calibration interval - no need to run a full calibration for just one sample
Less hands on time
Eliminates operator to operator issues associated with manual ELISA assays
Faster time to result - improved patient care
Malignant mesothelioma is an aggressive tumor with poor prognosis.
Clinical symptoms are not specific and most patients are referred and diagnosed late in the course of the disease.
A reliable histologic diagnosis of malignant mesothelioma can require performing multiple pleural biopsies, however many patients are not clinically able to undergo such invasive procedures.
Therefore, in patients with malignant pleural infusions and a clinical suspicion of malignant mesothelioma, a tumor marker assay is useful for assisting diagnosis, evaluating prognosis and monitoring response to treatment.